Keith Gottesdiener

Samsara BioCapital thesis

Dr. Thomas is a physician scientist, immunologist with more than 20 years of experience in academia, large pharmaceutical companies and biotech across multiple diverse therapeutic areas. She has been a venture partner at Samsara BioCapital since 2023 and is currently an independent board director for Allakos Therapeutics and Ventus Therapeutics. She is also a scientific advisor for AnaptysBio. Prior to Samsara, she was a board director for Chinook (acquired by Novartis in 2023) and held multiple roles in biotech companies including Executive Vice President, Head of Research and Development and

Sector and stage focus

• Seed: Pharmaceuticals, BioTech
• Series A: Pharmaceuticals, BioTech
• general: Boston / New England

Is Keith Gottesdiener a fit for your round?

Upload your pitch deck and see whether Keith Gottesdiener appears in your top 20 matches.